Chinese biotechnology companies—including Jiangsu Hengrui, CSPC Pharmaceutical Group, and Hansoh Pharmaceutical—are positioning themselves to bring their medications to global markets. Analysts predict these firms could emerge as powerful competitors to Western pharmaceutical giants within the next decade to 15 years.
- Chinese biotech outlicensing agreements projected to hit $240 billion in 2026
- Hengrui, CSPC, Hansoh among top candidates to enter US and EU markets
- Major collaborations with Western pharma provide capital for global expansion
What happened
Chinese biotechnology companies such as Jiangsu Hengrui Pharmaceuticals, CSPC Pharmaceutical Group, and Hansoh Pharmaceutical are gaining traction in licensing early-stage drugs to Western firms while preparing for independent commercialisation abroad. These companies have recently secured multibillion-dollar outlicensing deals granting Western partners rights to develop and market their drug candidates, including a $15.2 billion agreement between Hengrui and Bristol Myers Squibb, and an $18.5 billion deal between CSPC and AstraZeneca.
Such collaborations generate substantial revenue streams, enabling Chinese firms to invest in expanding their own drug portfolios and clinical trials targeting global markets, particularly in the US and Europe. Industry experts see this as a strategic pivot from purely licensing out assets toward launching self-branded medications internationally over the next 10 to 15 years.
Why it matters
The US pharmaceutical market remains the most lucrative worldwide, despite representing less than 5% of the global population. It accounts for roughly three-quarters of global pharmaceutical profits due to higher drug pricing and significant healthcare spending. Successfully entering this market could dramatically boost the growth trajectories of Chinese drugmakers and shift the global pharmaceutical competitive landscape.
Currently, Western companies like Pfizer, Roche, and AstraZeneca dominate this space. If Chinese biotech firms achieve independent commercialization in the US and Europe, it will mark a significant milestone in the internationalisation of China's pharmaceutical industry, establishing new global rivals and potentially reshaping drug innovation and distribution channels.
What to watch next
Investors and analysts will also be watching for additional deals, strategic partnerships, and possible initial market entries by Chinese firms. While only about one in four Chinese biopharma companies currently plan to commercialize independently overseas, larger players like Hengrui are expected to lead this push, potentially becoming the first true Chinese equivalents of pharmaceutical giants like Pfizer.